scholarly article | Q13442814 |
P2093 | author name string | Tariq M Rana | |
Jie Su | |||
Huricha Baigude | |||
Joshua McCarroll | |||
P2860 | cites work | RNAi-mediated gene silencing in non-human primates. | Q53630565 |
Visualizing a Correlation between siRNA Localization, Cellular Uptake, and RNAi in Living Cells | Q57360062 | ||
Design and creation of new nanomaterials for therapeutic RNAi | Q80155282 | ||
Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54 | Q21146051 | ||
Cellular cofactors affecting hepatitis C virus infection and replication | Q24317564 | ||
Improved targeting of miRNA with antisense oligonucleotides | Q24547511 | ||
MicroRNA targeting specificity in mammals: determinants beyond seed pairing | Q24607724 | ||
MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
miRiad roles for the miR-17-92 cluster in development and disease | Q24646970 | ||
miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates | Q24647285 | ||
Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver | Q24649633 | ||
The promises and pitfalls of RNA-interference-based therapeutics | Q24657247 | ||
MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms | Q24680714 | ||
MicroRNA-155 is induced during the macrophage inflammatory response | Q24683841 | ||
Interferon modulation of cellular microRNAs as an antiviral mechanism | Q27489711 | ||
The role of RNAi and microRNAs in animal virus replication and antiviral immunity | Q27490179 | ||
The functions of animal microRNAs | Q27860621 | ||
A microRNA polycistron as a potential human oncogene | Q27860720 | ||
Silencing of microRNAs in vivo with 'antagomirs' | Q27860891 | ||
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs | Q27861053 | ||
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA | Q27861124 | ||
bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila | Q28131827 | ||
The diverse functions of microRNAs in animal development and disease | Q28266193 | ||
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation | Q28268899 | ||
Control of stress-dependent cardiac growth and gene expression by a microRNA | Q28587851 | ||
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting | Q29547487 | ||
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection | Q29615959 | ||
LNA-mediated microRNA silencing in non-human primates | Q29615962 | ||
Illuminating the silence: understanding the structure and function of small RNAs | Q29622905 | ||
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs | Q34436572 | ||
MicroRNA functions in animal development and human disease | Q36285673 | ||
Cellular microRNA and P bodies modulate host-HIV-1 interactions | Q37391014 | ||
Delivery of therapeutic RNAi by nanovehicles | Q37581548 | ||
Tolerance for mutations and chemical modifications in a siRNA. | Q39698017 | ||
New hope for a microRNA therapy for liver cancer | Q39838405 | ||
Suppression of microRNA-silencing pathway by HIV-1 during virus replication | Q40166750 | ||
Potent RNAi by short RNA triggers. | Q41940226 | ||
siRNA function in RNAi: a chemical modification analysis | Q42044356 | ||
RNAi in human cells: basic structural and functional features of small interfering RNA. | Q44199577 | ||
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs | Q45147309 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 2.5 Generic | Q19113746 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | nanoparticle | Q61231 |
microRNA | Q310899 | ||
P304 | page(s) | e38 | |
P577 | publication date | 2011-01-06 | |
P1433 | published in | Nucleic Acids Research | Q135122 |
P1476 | title | Silencing microRNA by interfering nanoparticles in mice | |
P478 | volume | 39 |
Q92581957 | Adenylyl cyclase‑associated protein 1‑targeted nanoparticles as a novel strategy for the treatment of metastatic non‑small cell lung cancer |
Q37947912 | Breast cancer and microRNAs: therapeutic impact. |
Q38112723 | Canonical and non-canonical barriers facing antimiR cancer therapeutics |
Q42373834 | Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors |
Q26999187 | Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives |
Q35039281 | Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy |
Q36487134 | Gene regulation by non-coding RNAs |
Q39351982 | Interfering nanoparticles for silencing microRNAs |
Q36901850 | Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma |
Q36037933 | MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review |
Q38002726 | MicroRNA silencing and the development of novel therapies for liver disease |
Q38184973 | MicroRNAs and human diseases: diagnostic and therapeutic potential |
Q26752710 | MicroRNAs as regulators of apoptosis mechanisms in cancer |
Q37381107 | MicroRNAs as therapeutic targets in chemoresistance |
Q34599354 | MicroRNAs in Cancer Biology and Therapy: Current Status and Perspectives |
Q37292279 | MicroRNAs in Head and Neck Cancer |
Q33880442 | MicroRNAs in liver disease |
Q37937737 | MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality |
Q24595213 | Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma |
Q37139278 | Non-coding RNAs and cancer |
Q30632163 | Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy. |
Q37510967 | Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer |
Q37478933 | Progress in microRNA delivery |
Q37984588 | Recent trends in cancer drug resistance reversal strategies using nanoparticles |
Q26777595 | Role and Function of MicroRNAs in Extracellular Vesicles in Cardiovascular Biology |
Q38285749 | Strategies to antagonize miRNA functions in vitro and in vivo |
Q34278112 | The duality of oncomiR addiction in the maintenance and treatment of cancer |
Q38391282 | The role of hypoxia-induced miR-210 in cancer progression |
Q37991391 | Therapeutic modulation of miRNA for the treatment of proinflammatory lung diseases. |
Q38228101 | Therapeutic targeting of microRNAs: current status and future challenges |
Q35828495 | Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer |
Q52682041 | Tumor-Targeting Anti-MicroRNA-155 Delivery Based on Biodegradable Poly(ester amine) and Hyaluronic Acid Shielding for Lung Cancer Therapy. |
Search more.